Clinical diagnostics company Luminex Corporation (NASDAQ:LMNX) revealed on Friday the receipt of Food and Drug Administration (FDA) Emergency Use Authorization (EUA) for its high-throughput, scalable, cost-effective NxTAG CoV extended panel for the detection of the SARS-CoV-2 virus.
According to the company, the high complexity molecular laboratories can now use the NxTAG test on its easy-to-use, compact MAGPIX System to rapidly detect the virus that causes COVID-19 disease for up to 96 patients in approximately four hours.
Based on the company's bead-based chemistry, the MAGPIX System is both easy to run and to use, providing a cost-effective testing solution for the rapid delivery of results. The NxTAG CoV Extended Panel can be run in parallel with the NxTAG Respiratory Pathogen Panel (RPP).
In conjunction, the company has expanded its manufacturing capacity to produce up to 300,000 NxTAG tests per month, with the majority of that capacity focused on SARS-CoV-2.
Additionally, the company received USD642,000, which is 36% of the total programme cost, through from the Biomedical Advanced Research and Development Authority (BARDA) to develop and validate the NxTAG SARS-CoV-2 Test. This project has been funded in whole or in part with federal funds from the Department of Health and Human Services, Office of the Assistant Secretary for Preparedness and Response and Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures.
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients
Soligenix receives orphan drug designation from FDA for active ingredient in SuVax
Candel Therapeutics granted FDA Orphan Drug Designation for CAN-2409 in pancreatic cancer treatment
Lipogems completes patient enrolment in ARISE I US FDA IDE study
Amylyx Pharmaceuticals' AMX0035 shows promising impact on Wolfram syndrome symptoms
Roche attains CE Mark for first companion diagnostic for HER2-low metastatic breast cancer
Cadrenal Therapeutics' tecarfarin receives US FDA Orphan Drug Designation
BioCity Biopharma's BC2027 Phase one study IND application receives US FDA approval
Seres Therapeutics completes patient enrollment for SER-155 Phase 1B trial